Therna Biosciences is a San Francisco, CA–based company developing RNA medicines that combine deep RNA biology with generative AI. Its biology-guided platform enables rapid, end-to-end design of precisely engineered mRNA molecules optimized for enhanced translation, stability, immune evasion, and tissue-specific expression. The platform also identifies optimal target sites within mRNA to enable effective ASO and siRNA design, allowing gene expression to be upregulated, downregulated, or finely tuned. Therna positions these capabilities across therapeutic areas including genetic and rare diseases, ophthalmology, and immunology. The company was co-founded by Nazli Azimi, Ph.D., and Hani Goodarzi, Ph.D., who bring experience in drug development, RNA biology, and generative AI. Therna raised $10M in seed funding and intends to use the proceeds to expand its development efforts.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2025